Oxana Iliach is a Senior Director of Regulatory Strategy at Certara (PA, USA), a biotech company that offers comprehensive solutions for transforming and accelerating drug development. In her spare ...

Bringing a single drug to market can take more than a decade and cost billions of dollars, with fewer than one in ten candidates successfully reaching approval. Against this backdrop, generative AI is ...

FDA moves shaping drug development and oversight include new gene therapy guidance, clinical trial transparency efforts, and recent drug approvals.

As viruses evolve to resist vaccines and therapeutics, new targeted approaches to deliver broad-spectrum antivirals are needed. In this podcast, Anil Diwan, President and Executive Chairman of ...

A Luxembourg-based start-up has raised $10 million to help the pharmaceutical sector exploit the power of AI to drive faster ...

Overcoming common challenges with today’s biologics, such as developing devices for high-concentration subcutaneous administration, can accelerate the launch of novel products, reduce risks, and ...

AWS's new AI platform grants researchers direct access to a broad library of biological foundation models for lab-in-the-loop drug discovery.

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) The following represents ...

From survivorship bias to root causes! Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening ...

Global CPHI events underscore international sourcing and partnership dynamics, with Shanghai’s CPHI & PMEC China illustrating ...